| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
Proxy statement: annual meeting on December 15, 2026
CEO pay $6.6M, up 20% · say-on-pay vote |
| 26 Oct 2026 | DEFA14A |
| 26 Oct 2026 | ARS |
| 23 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 |
| 16 Oct 2026 | PRE 14A |
| 09 Oct 2026 |
Form 4: Schayowitz Adam, EVP, Head of R&D
Received 37,037 shares by exercise or conversion · Sold 13,832 shares ($358K) |
| 09 Oct 2026 | 144 |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
NEITHER THIS DEBT INSTRUMENT NOR THE NOTES ISSUED IN CONNECTION HEREWITH HAVE BEEN REGISTERED UNDER THE SECURITIES ACT (AS DEFINED BELOW), OR ANY APPLICABLE STATE SECURITIES LAWS. SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSE... |
| 25 Aug 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 06 Jul 2026 |
Form 4: Hollywood Mark, EVP & Chief Operating Officer
Received 939 shares as a grant or award ($20.9K) |
| 29 Jun 2026 | 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure |
| 15 May 2026 |
Form 4: Schneider Paul R, EVP, General Counsel
Granted 178,000 Stock Option (Right to Buy) · Granted 119,000 Restricted Stock Unit |
| 15 May 2026 |
Form 3: Schneider Paul R, EVP, General Counsel
Holds 0 shares of No securities are beneficially owned |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 07 May 2026 | 10-Q |
| 07 May 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 15 Apr 2026 | SCHEDULE 13G |
Loading...
